Lecozotan

Lecozotan (SRA-333) is a selective 5-HT1A receptor antagonist developed for Alzheimer's disease research. It enhances potassium-stimulated glutamate and acetylcholine release in the hippocampus, improving cognition in rat models without inducing tolerance or affecting anxiety. This compound is a valuable tool for in vivo and in vitro studies of cognitive function and cholinergic/glutamatergic neurotransmission.